Seaport Therapeutics
SPTX20.4600.00% ( 0.000 )
Seaport Therapeutics (SPTX)
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 20.460
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 23.000
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Seaport Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 30, 2026Price forecast
$38.0085.73%
Forecast & RatingBuy
6analysts
- Strong buy66.67%
- Buy16.67%
- Hold16.67%
- Sell0.00%
- Strong sell0.00%
News
- Earnings Watch · 2 hours ago
Seaport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · 2 hours ago
Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 million
- PUBT · Jun 24 at 05:05 AM
Seaport Therapeutics director Robert J. Hombach trust buys 13,000 shares worth $235,768
- Tip Ranks · Jun 9 at 10:29 AM
3 Best Stocks to Buy Today, 6/9/2026, According to Top Analysts
- benzinga_article · Jun 9 at 09:55 AM
Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers.
- Baystreet · Jun 8 at 09:15 AM
Seaport Pops on Q1 Numbers
